The present article describes the preparation of beta emitter lutetium-177-lebeled zirconia colloid and its preliminary physico-chemical and biological evaluation of suitability for local radionuclide therapy. The new 177 Lu-labeled therapeutic radiopharmaceutical candidate was based on the synthesis mode of a previously described zirconia nanoparticle system. Morphology and size of developed radiopharmaceutical compound were evaluated through scanning electron microscope and dynamic light scattering methods. The radiocolloid had a 1.7 micrometer mean diameter and showed suitable radiolabeling and colloid size in vitro stability at RT and during blood sera stability test. After the in vitro characterizations, the product was investigated in the course of the treatment of a spontaneously diseased dog veterinary patient's hock joint completed with SPECT imaging follow-up measurements and a dualisotope SPECT imaging tests with conventional 99m Tc-MDP bone scintigraphy. In the treated dog any clinical side effects or signs of histopatological alterations of the joints could not be observed during the treatment. SPECT follow-up studies unequivocally showed appropriately high localization of the 177 Lu-labeled colloid in hock joint and detectable but negligible radiocolloid leakages in the nearest lymph node, respectively. -l a b e l e d z i r c o n i a p a r t i c l e s f o r r a d i o s y n o v e c t o m y 
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Introduction
Localized irradiation of the synovial lining of a joint has emerged as one of the most successful modality for the treatment of rheumatoid arthritis [1] . Local radiation therapy can be effected by intraarticular administration of suitable beta-emitting radionuclides which are bound to colloidal size range particles. This treatment is known as radiosynovectomy (RS) or radiosynoviorthesis (RSV). Numerous beta-emitting (usually lanthanide) radioisotope was used Zirconia, a ceramic material is used for the synthesis of nanoparticle systems [7, 8] and for other biomedical applications e.g. in dental implants [9] . It is known to be biocompatible [10, 11] , and our preliminary experiments have shown that zirconia is also biodegradable under certain circumstances [12] Lu for the intraarticular injection of therapeutic dose to the joints, as well.
Besides biocompatibility and biodegradability, the most important attributes of radionuclide carrier colloids, microparticulates focusing as the carrier of radionuclides for intra-arterial therapy are appropriate particle size distribution and high radiochemical stability to overcome the possible in vivo leaching of the radioisotope [13] . In the present study, we have explored the possibility of a zirconia particulate system above one micrometer effective mean particle size.
In this present study the new product was investigated in the course of the radionuclide therapy of a spontaneously diseased dog veterinary patient's hock joint. As previously, the objective of treatment of a veterinary patient was to provide a preliminary preclinical proof of concept of a potential prospective human medical application and pharmaceutical before the further detailed evaluations [12, 14, 15] . Absolute ethanol (a.r., >99.7%, < 0.2% water, Reanal), cesium chloride (CsCl, Specpure, trace metal basis); zirconium(IV) butoxide (TBOZ, 80 wt% in butanol, Sigma-Aldrich) were used for ZrO 2 synthesis. TBOZ was kept and manipulated under argon gas. Ultrapure water was collected from a MilliQ System. HEPES buffer solution (1M, 59205C) was purchased from Sigma-Aldrich.
Preparation of 177 Lu-labeled zirconia particles
The 177 Lu-labeled colloid was based on previously prepared and described zirconia nanoparticle system [16, 17] . Briefly, 100 ml of abs. ethanol was stirred at 300 rpm and heated to 60°C in a 
In vitro characterization of labeled zirconia particles
To evaluate its in vitro stability,
177
Lu-labeled zirconia colloid was kept at 21°C up to 1 week after the preparation and particle size distribution and 177
Lu-labeling yield were investigated after 1, 8, 24 and 168 hours. Labelling efficiency was examined by thin layer chromatography (ITLC-SG, silica gel impregnated glass fiber plates, Gelman Sciences Inc). In vitro serum stability was evaluated in canine blood serum. A 20-µL aliquot of radiolabeled product was added to 500 µL of serum. Sample was stored at 37°C and radioabeling yield was evaluated at 1, 8, 24 and 168 hours of incubation using the same ITLC-SG method.
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Morphological investigation of the zirconia particles was carried out on a ZEISS EVO 40XVP Besides the SPECT imaging follow-up, serial blood and urine samples were collected and analyzed to detect potential excretion ratio of injected radioactivity through these pathways. 
Results and Discussion
In vitro characterization results
Morphology and particle size distribution of the product were examined through SEM and DLS and it could be concluded that zirconia particles, which were originally nearly 380 nm of diameter [17] were partially dispersed in HEPES buffer, and by this means we could obtain loosely packed inorganic aggregates (Fig 1) . Over micron size aggregates remain in the slurry with a mean diameter of 1.7 micrometer according to the DLS size distribution function ( The radiolabeled colloid showed high in vitro radiochemical and colloid size stability. The labeling efficiency of the sample incubated at room temperature was found to be above 99% -l a b e l e d z i r c o n i a p a r t i c l e s f o r r a d i o s y n o v e c t o 
Results of biological study
In 
